References
- Bobek K., Cepelak V. Butazolidin als antithromboticum. Gynaecologia 1958; 145: 434, 4441. Bobek K., Cepelak V. Butazolidin als antithromboticum. Gynaecologia 1958; 145: 434, 444
- Dallin C. Therapeutic Drugs. Churchill Livingstone, Edinburgh 19912. Dallin C. Therapeutic Drugs. Churchill Livingstone, Edinburgh 1991
- D'Angelo A., Kluft C., Verheijen J. H., Rijken D. C., Mozzi E, Manucci P. M. Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Europ. J. Clin. Invest. 1958; 15: 308, 3123. D'Angelo A., Kluft C., Verheijen J. H., Rijken D. C., Mozzi E, Manucci P. M. Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Europ. J. Clin. Invest. 1958; 15: 308, 312
- Di Minno G., Mancini M. Drugs affecting fibrinogen level. Cardiovasc. Drugs Ther. 1992; 6: 25, 274. Di Minno G., Mancini M. Drugs affecting fibrinogen level. Cardiovasc. Drugs Ther. 1992; 6: 25, 27
- Gryglewski R. J. The fibrinolytic activity of anti-inflammatory drugs. J. Pharm. Pharmac. 1966; 18: 4745. Gryglewski R. J. The fibrinolytic activity of anti-inflammatory drugs. J. Pharm. Pharmac. 1966; 18: 474
- Gryglewski R. J. On the mechanism of fibrinolysis induced by anti-inflammatory drugs. Chemical Control of Fibrinolysis-Thronibolysis, J. M. Schor. Wiley-Interscience, New York 1970; 446. Gryglewski R. J. On the mechanism of fibrinolysis induced by anti-inflammatory drugs. Chemical Control of Fibrinolysis-Thronibolysis, J. M. Schor. Wiley-Interscience, New York 1970; 44
- Heinrich R., Castell J. V., Andus T. Interleukin-6 and the acute phase response. Biochem. J. 1990; 265: 621, 6367. Heinrich R., Castell J. V., Andus T. Interleukin-6 and the acute phase response. Biochem. J. 1990; 265: 621, 636
- Kluft C., Verheijen J. H., Jie A. F. H., Rijken D. C., Preston F. E., Sue-Ling H. M., Jespersen J., Aasen A. O. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand. J. Clin. Lab. Invest. 1985; 45: 605, 6108. Kluft C., Verheijen J. H., Jie A. F. H., Rijken D. C., Preston F. E., Sue-Ling H. M., Jespersen J., Aasen A. O. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand. J. Clin. Lab. Invest. 1985; 45: 605, 610
- Nielsen H. K., Husted S. E., Krusell L. R., Fasting H., Charles P., Hansen H. H., Nielsen B. O., Petersen J. B., Bechgaard P. Anticoagulant therapy in deep venous thrombosis. A randomized controlled study. Thromb. Res. 1994; 73: 215, 2269. Nielsen H. K., Husted S. E., Krusell L. R., Fasting H., Charles P., Hansen H. H., Nielsen B. O., Petersen J. B., Bechgaard P. Anticoagulant therapy in deep venous thrombosis. A randomized controlled study. Thromb. Res. 1994; 73: 215, 226
- Sigg K. Ueber die Behandlung der Phlebitis mit Butazolidin. Praxis 1954; 43: 172, 17410. Sigg K. Ueber die Behandlung der Phlebitis mit Butazolidin. Praxis 1954; 43: 172, 174
- Swaim W. R., Feders M. B. Fibrinogen assay. Clin. Chemistry 1967; 13: 1026, 102811. Swaim W. R., Feders M. B. Fibrinogen assay. Clin. Chemistry 1967; 13: 1026, 1028
- Szczepaski M., Duchiski T., Kretowicz P. Single dose of nandrolone does not prevent postoperative fibrinolytic shutdown. Fibrinolysis 1995; 9: 350, 35512. Szczepaski M., Duchiski T., Kretowicz P. Single dose of nandrolone does not prevent postoperative fibrinolytic shutdown. Fibrinolysis 1995; 9: 350, 355
- Tillberg B. N. Prophylaxis of postoperative venous thrombosis. Acta Orthop. Scand. Suppl. 158. Munksgaard, Copenhagen 197413. Tillberg B. N. Prophylaxis of postoperative venous thrombosis. Acta Orthop. Scand. Suppl. 158. Munksgaard, Copenhagen 1974